WO2009121872A3 - Tetrahydroisoquinolines, pharmaceutical compositions containing them, and their use in therapy - Google Patents

Tetrahydroisoquinolines, pharmaceutical compositions containing them, and their use in therapy Download PDF

Info

Publication number
WO2009121872A3
WO2009121872A3 PCT/EP2009/053800 EP2009053800W WO2009121872A3 WO 2009121872 A3 WO2009121872 A3 WO 2009121872A3 EP 2009053800 W EP2009053800 W EP 2009053800W WO 2009121872 A3 WO2009121872 A3 WO 2009121872A3
Authority
WO
WIPO (PCT)
Prior art keywords
tetrahydroisoquinolines
pharmaceutical compositions
therapy
compositions containing
relates
Prior art date
Application number
PCT/EP2009/053800
Other languages
French (fr)
Other versions
WO2009121872A2 (en
Inventor
Wilhelm Amberg
Michael Ochse
Udo Lange
Wilfried Braje
Berthold Behl
Wilfried Hornberger
Mario Mezler
Charles W. Hutchins
Original Assignee
Abbott Gmbh & Co. Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Gmbh & Co. Kg filed Critical Abbott Gmbh & Co. Kg
Priority to ES09727055T priority Critical patent/ES2397764T3/en
Priority to MX2010010773A priority patent/MX2010010773A/en
Priority to JP2011502370A priority patent/JP5554319B2/en
Priority to CA2720004A priority patent/CA2720004A1/en
Priority to CN200980121237.2A priority patent/CN102083797B/en
Priority to US12/933,326 priority patent/US8653100B2/en
Priority to EP09727055A priority patent/EP2271625B1/en
Publication of WO2009121872A2 publication Critical patent/WO2009121872A2/en
Publication of WO2009121872A3 publication Critical patent/WO2009121872A3/en
Priority to US13/792,105 priority patent/US8957089B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
    • C07D217/18—Aralkyl radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/08—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing alicyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

The present invention relates to tetrahydroisoquinoline of the formula (I) or a physiologically tolerated salt thereof. The invention relates to pharmaceutical compositions comprising such tetrahydroisoquinolines, and the use of such tetrahydroisoquinolines for therapeutic purposes. The tetrahydroisoquinolines are GIyT1 inhibitors.
PCT/EP2009/053800 2008-04-01 2009-03-31 Tetrahydroisoquinolines, pharmaceutical compositions containing them, and their use in therapy WO2009121872A2 (en)

Priority Applications (8)

Application Number Priority Date Filing Date Title
ES09727055T ES2397764T3 (en) 2008-04-01 2009-03-31 Tetrahydroisoquinolines, pharmaceutical compositions containing them, and their use in therapy
MX2010010773A MX2010010773A (en) 2008-04-01 2009-03-31 Tetrahydroisoquinolines, pharmaceutical compositions containing them, and their use in therapy.
JP2011502370A JP5554319B2 (en) 2008-04-01 2009-03-31 Tetrahydroisoquinolines, pharmaceutical compositions containing them and their use in therapy
CA2720004A CA2720004A1 (en) 2008-04-01 2009-03-31 Tetrahydroisoquinolines, pharmaceutical compositions containing them, and their use in therapy
CN200980121237.2A CN102083797B (en) 2008-04-01 2009-03-31 Tetrahydroisoquinolines, pharmaceutical compositions containing them, and their use in therapy
US12/933,326 US8653100B2 (en) 2008-04-01 2009-03-31 Tetrahydroisoquinolines, pharmaceutical compositions containing them, and their use in therapy
EP09727055A EP2271625B1 (en) 2008-04-01 2009-03-31 Tetrahydroisoquinolines, pharmaceutical compositions containing them, and their use in therapy
US13/792,105 US8957089B2 (en) 2008-04-01 2013-03-10 Tetrahydroisoquinolines, pharmaceutical compositions containing them, and their use in therapy

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US4131308P 2008-04-01 2008-04-01
US61/041,313 2008-04-01

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US12/933,326 A-371-Of-International US8653100B2 (en) 2008-04-01 2009-03-31 Tetrahydroisoquinolines, pharmaceutical compositions containing them, and their use in therapy
US13/792,105 Division US8957089B2 (en) 2008-04-01 2013-03-10 Tetrahydroisoquinolines, pharmaceutical compositions containing them, and their use in therapy

Publications (2)

Publication Number Publication Date
WO2009121872A2 WO2009121872A2 (en) 2009-10-08
WO2009121872A3 true WO2009121872A3 (en) 2010-01-14

Family

ID=40687932

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2009/053800 WO2009121872A2 (en) 2008-04-01 2009-03-31 Tetrahydroisoquinolines, pharmaceutical compositions containing them, and their use in therapy

Country Status (8)

Country Link
US (2) US8653100B2 (en)
EP (2) EP2271625B1 (en)
JP (1) JP5554319B2 (en)
CN (2) CN102083797B (en)
CA (1) CA2720004A1 (en)
ES (1) ES2397764T3 (en)
MX (1) MX2010010773A (en)
WO (1) WO2009121872A2 (en)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8653100B2 (en) 2008-04-01 2014-02-18 Abbvie Inc. Tetrahydroisoquinolines, pharmaceutical compositions containing them, and their use in therapy
TW201038569A (en) * 2009-02-16 2010-11-01 Abbott Gmbh & Co Kg Heterocyclic compounds, pharmaceutical compositions containing them, and their use in therapy
AR075442A1 (en) 2009-02-16 2011-03-30 Abbott Gmbh & Co Kg AMINOTETRALINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM AND THEIR USES IN THERAPY
US9045459B2 (en) * 2010-08-13 2015-06-02 AbbVie Deutschland GmbH & Co. KG Phenalkylamine derivatives, pharmaceutical compositions containing them, and their use in therapy
US8846743B2 (en) 2010-08-13 2014-09-30 Abbott Laboratories Aminoindane derivatives, pharmaceutical compositions containing them, and their use in therapy
US9051280B2 (en) 2010-08-13 2015-06-09 AbbVie Deutschland GmbH & Co. KG Tetraline and indane derivatives, pharmaceutical compositions containing them, and their use in therapy
US8883839B2 (en) * 2010-08-13 2014-11-11 Abbott Laboratories Tetraline and indane derivatives, pharmaceutical compositions containing them, and their use in therapy
US8877794B2 (en) 2010-08-13 2014-11-04 Abbott Laboratories Phenalkylamine derivatives, pharmaceutical compositions containing them, and their use in therapy
US9309200B2 (en) * 2011-05-12 2016-04-12 AbbVie Deutschland GmbH & Co. KG Benzazepine derivatives, pharmaceutical compositions containing them, and their use in therapy
WO2013020930A1 (en) * 2011-08-05 2013-02-14 Abbott Gmbh & Co. Kg Aminochromane, aminothiochromane and amino-1,2,3,4-tetrahydroquinoline derivatives, pharmaceutical compositions containing them, and their use in therapy
JP2014533675A (en) 2011-11-18 2014-12-15 アッヴィ・ドイチュラント・ゲー・エム・ベー・ハー・ウント・コー・カー・ゲー N-substituted aminobenzocycloheptene, aminotetralin, aminoindane and phenalkylamine derivatives, pharmaceutical compositions containing them, and their use in therapy
US9365512B2 (en) * 2012-02-13 2016-06-14 AbbVie Deutschland GmbH & Co. KG Isoindoline derivatives, pharmaceutical compositions containing them, and their use in therapy
US9656955B2 (en) 2013-03-15 2017-05-23 Abbvie Inc. Pyrrolidine derivatives, pharmaceutical compositions containing them, and their use in therapy
US9650334B2 (en) 2013-03-15 2017-05-16 Abbvie Inc. Pyrrolidine derivatives, pharmaceutical compositions containing them, and their use in therapy
JP2016533375A (en) 2013-10-17 2016-10-27 アッヴィ・ドイチュラント・ゲー・エム・ベー・ハー・ウント・コー・カー・ゲー Aminotetralin derivatives and aminoindan derivatives, pharmaceutical compositions containing them, and their use in therapy
AU2014336153A1 (en) 2013-10-17 2016-04-28 AbbVie Deutschland GmbH & Co. KG Aminochromane, aminothiochromane and amino-1,2,3,4-tetrahydroquinoline derivatives, pharmaceutical compositions containing them, and their use in therapy
US9550754B2 (en) 2014-09-11 2017-01-24 AbbVie Deutschland GmbH & Co. KG 4,5-dihydropyrazole derivatives, pharmaceutical compositions containing them, and their use in therapy
CN105130893B (en) * 2015-09-08 2018-04-10 大连理工大学 A kind of application of the first boc methyl tetrahydro isoquinoline derivative of 1 benzyl 6, preparation method and its platelet aggregation-against
ES2819841T3 (en) * 2016-04-13 2021-04-19 UCB Biopharma SRL Tetrahydroisoquinoline derivatives
CN114957049B (en) * 2022-06-13 2023-10-03 河北冠龙农化有限公司 Synthesis method of N-phenyl-N-trichloromethylthiobenzene sulfonamide

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993013073A1 (en) * 1991-12-23 1993-07-08 The Boots Company Plc Substituted tetrahydroisoquinolines and their use as therapeutic agents

Family Cites Families (111)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8004002L (en) 1980-05-29 1981-11-30 Arvidsson Folke Lars Erik THERAPEUTICALLY APPLICABLE TETRALIN DERIVATIVES
ATE39483T1 (en) 1982-04-02 1989-01-15 Takeda Chemical Industries Ltd CONDENSED PYRROLINONE DERIVATIVES AND THEIR PREPARATION.
US4789678A (en) 1986-08-25 1988-12-06 Hoechst-Roussel Pharmaceuticals, Inc. Memory enhancing α-alkyl-4-amino-3-quinolinemethanols and 1-(4-aralkylamino-3-quinolinyl)alkanones and related compounds
US4927838A (en) 1987-07-10 1990-05-22 Hoffman-La Roche Inc. Pyridine compounds which are useful in treating a disease state characterized by an excess of platelet activating factors
ZA885824B (en) 1987-08-14 1989-04-26 Merrell Dow Pharma Novel antidepressants
US5300523A (en) 1988-07-28 1994-04-05 Bayer Aktiengesellschaft Substituted aminomethyltetralins and their heterocyclic analogues
RU2086535C1 (en) 1989-05-31 1997-08-10 Дзе Апджон Компани Derivatives of 1,2,3,4-tetrahydro-2-naphthylamine
US5545755A (en) 1989-05-31 1996-08-13 The Upjohn Company Therapeutically useful 2-aminotetralin derivatives
US5071875A (en) 1989-09-25 1991-12-10 Northwestern University Substituted 2-amidotetralins as melatonin agonists and antagonists
KR100207876B1 (en) 1990-10-12 1999-07-15 로버트 에이. 아미테이지 Therapeutically useful 2-aminotetralin derivatives
JPH06506951A (en) 1991-04-26 1994-08-04 ジ・アップジョン・カンパニー Substance abuse treatment/prevention methods
JPH05213884A (en) 1991-06-14 1993-08-24 Upjohn Co:The Novel 4-aminoquinoline and prophylatic/ therapeutic agent for hypertensive/congestive heart failure using same as effective component
MY115155A (en) 1993-09-09 2003-04-30 Upjohn Co Substituted oxazine and thiazine oxazolidinone antimicrobials.
ES2214546T3 (en) 1995-09-15 2004-09-16 PHARMACIA & UPJOHN COMPANY N-OXIDES OF AMINOARILOXAZOLIDINONA.
WO1997045115A1 (en) 1996-05-31 1997-12-04 Trophix Pharmaceuticals, Inc. Pharmaceutical for treatment of neurological and neuropsychiatric disorders
US6083986A (en) 1996-07-26 2000-07-04 Icagen, Inc. Potassium channel inhibitors
US6057357A (en) 1997-04-30 2000-05-02 Warner-Lambert Company Peripherally selective kappa opioid agonists
AU7552198A (en) 1997-06-11 1998-12-30 Sankyo Company Limited Benzylamine derivatives
US6060491A (en) 1997-06-19 2000-05-09 Dupont Pharmaceuticals 6-membered aromatics as factor Xa inhibitors
US20030220234A1 (en) 1998-11-02 2003-11-27 Selvaraj Naicker Deuterated cyclosporine analogs and their use as immunodulating agents
NZ510988A (en) 1998-10-07 2005-01-28 Ortho Mcneil Pharm Inc N-aralkylaminotetralins useful as ligands for the neuropeptide Y5 receptor
WO2001007411A1 (en) 1999-07-26 2001-02-01 Banyu Pharmaceutical Co., Ltd. Biarylurea derivatives
RU2228927C2 (en) 1999-07-28 2004-05-20 Орто-Макнейл Фармасьютикал, Инк. Derivatives of amines or amides, pharmaceutical composition based on thereof and method for antagonizing receptor y5 of neuropeptide npy
GB9918037D0 (en) 1999-07-30 1999-09-29 Biochemie Gmbh Organic compounds
US6426364B1 (en) * 1999-11-01 2002-07-30 Nps Allelix Corp. Diaryl-enynes
JP4850332B2 (en) * 2000-10-18 2012-01-11 東京エレクトロン株式会社 Etching method of dual damascene structure
IL157093A0 (en) * 2001-03-27 2004-02-08 Actelion Pharmaceuticals Ltd 1,2,3,4-tetrahydroisoquinolines derivatives as urotensin ii receptor antagonists
AU2756602A (en) 2001-04-25 2002-10-31 Pfizer Products Inc. Methods and kits for treating depression or preventing deterioration of cognitive function
US6831193B2 (en) 2001-05-18 2004-12-14 Abbott Laboratories Trisubstituted-N-[(1S)-1,2,3,4-Tetrahydro-1-naphthalenyl]benzamides which inhibit P2X3 and P2X2/3 containing receptors
EP1284257B1 (en) 2001-08-16 2005-10-05 Pfizer Products Inc. Difluoromethylene aromatic ethers and their use as inhibitors of the glycine type-1 transporter
DE10149370A1 (en) 2001-10-06 2003-04-10 Merck Patent Gmbh New 1-(phenyl or pyridinyl)-1H-pyrazole derivatives, are glycine transporter inhibitors useful e.g. for treating schizophrenia, depression, dementia, neurodegenerative diseases or pain
ATE447561T1 (en) 2001-11-21 2009-11-15 Pharmacia & Upjohn Co Llc SUBSTITUTED ARYL 1,4-PYRAZINE DERIVATIVES
DE60219521T2 (en) 2001-12-20 2007-08-16 H. Lundbeck A/S ARYLOXYPHENYL AND ARYLSULFANYLPHENYL DERIVATIVES
GB0130696D0 (en) 2001-12-21 2002-02-06 Smithkline Beecham Plc Chemical Compounds
DE10210779A1 (en) * 2002-03-12 2003-10-09 Merck Patent Gmbh Cyclic amides
DE10217006A1 (en) * 2002-04-16 2003-11-06 Merck Patent Gmbh Substituted indoles
FR2838739B1 (en) 2002-04-19 2004-05-28 Sanofi Synthelabo N- [PHENYL (PIPERIDIN-2-YL) METHYL) BENZAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION
ATE533743T1 (en) 2002-05-17 2011-12-15 Janssen Pharmaceutica Nv UREA DERIVATIVES OF AMINOTETRALIN AS MODULATORS OF THE VANILLOID RECEPTOR VR1
DE60330485D1 (en) 2002-07-15 2010-01-21 Merck & Co Inc FOR THE TREATMENT OF DIABETES
FR2842804B1 (en) 2002-07-29 2004-09-03 Sanofi Synthelabo N- [PHENYL (PIPERIDIN-2-YL) METHYL] BENZAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION
FR2842805A1 (en) 2002-07-29 2004-01-30 Sanofi Synthelabo N- [PHENYL (PIPERIDIN-2-YL) METHYL] BENZAMIDE DERIVATIVES, THEIR PREPARATION AND APPLICATION THERAPEUTICS
US20040152741A1 (en) 2002-09-09 2004-08-05 Nps Allelix Corporation Arylglycine derivatives and their use as glycine transport inhibitors
US7084154B2 (en) 2003-02-11 2006-08-01 Pharmacopeia Drug Disclovery, Inc. 2-(aminomethyl) arylamide analgesics
ATE340782T1 (en) 2003-02-17 2006-10-15 Hoffmann La Roche PIPERIDINEBENZENESULFONAMIDE DERIVATIVES
MXPA05009508A (en) 2003-03-07 2005-12-14 Lilly Co Eli 6-substituted nicotinamide derivatives as opioid receptor antagonists.
DE10315570A1 (en) 2003-04-05 2004-10-14 Merck Patent Gmbh New 1-aryl-1,2,3-triazole derivatives useful for treating e.g. schizophrenia, depression, dementia, Parkinson's disease or Alzheimer's disease, are glycine transporter inhibitors
AU2004233942A1 (en) 2003-04-30 2004-11-11 H. Lundbeck A/S Aromatic oxyphenyl and aromatic sulfanylphenyl derivatives
JP2004359633A (en) 2003-06-06 2004-12-24 Bayer Cropscience Ag Utilization of isoindolinone derivative as insecticide
GB0314479D0 (en) 2003-06-20 2003-07-23 Glaxo Group Ltd Compounds
GB0314476D0 (en) 2003-06-20 2003-07-23 Glaxo Group Ltd Compounds
GB0314478D0 (en) 2003-06-20 2003-07-23 Glaxo Group Ltd Compounds
MXPA06001665A (en) * 2003-08-11 2006-04-28 Hoffmann La Roche Piperazine with or-substituted phenyl group and their use as glyt1 inhibitors.
MXPA06002727A (en) * 2003-09-09 2006-06-05 Hoffmann La Roche 1- (2-amino-benzol) -piperazine derivatives as glycine uptake inhibitors for the treatment of psychoses.
KR100774621B1 (en) * 2003-09-09 2007-11-14 에프. 호프만-라 로슈 아게 1-benzoyl-piperazine derivatives as glycine uptake inhibitors for the treatment of psychoses
FR2861070B1 (en) * 2003-10-17 2006-01-06 Sanofi Synthelabo DERIVATIVES OF N- [PHENYL (PYRROLIDIN-2-YL) METHYL] BENZAMIDE AND N - [(AZEPAN-2-YL) PHENYLMETHYL] BENZAMIDE, THEIR PREPARATION AND THEIR THERAPEUTIC USE
FR2861073B1 (en) * 2003-10-17 2006-01-06 Sanofi Synthelabo N- [HETEROARYL (PIPERIDIN-2-YL) METHYL] BENZAMIDE DERIVATIVES, THEIR PREPARATION AND THERAPEUTIC USE THEREOF
FR2861076B1 (en) 2003-10-17 2006-01-06 Sanofi Synthelabo N-HETEROCYCLYMETHYLBENZAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC USE
FR2861074B1 (en) 2003-10-17 2006-04-07 Sanofi Synthelabo N- [PHENYL (PIPERIDIN-2-YL) METHYL] BENZAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC USE
FR2861071B1 (en) * 2003-10-17 2006-01-06 Sanofi Synthelabo N- [PHENYL (ALKYLPIPERIDIN-2-YL) METHYL] BENZAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC USE
EP1678177B1 (en) 2003-10-23 2007-11-28 F.Hoffmann-La Roche Ag Triaza-spiropiperidine derivatives for use as glyt-1 inhibitors in the treatment of neurological and neuropsychiatric disorders
AU2004289290A1 (en) 2003-11-12 2005-05-26 Merck & Co., Inc. 4-phenyl piperdine sulfonyl glycine transporter inhibitors
GB0326840D0 (en) 2003-11-18 2003-12-24 Glaxo Group Ltd Compounds
WO2005058317A1 (en) 2003-12-18 2005-06-30 Glaxo Group Limited Glycine transporter-1 inhibirors
WO2005058885A2 (en) 2003-12-18 2005-06-30 Glaxo Group Limited Piperidine derivatives and their use as glycine transporter inhibitors
GB0329362D0 (en) 2003-12-18 2004-01-21 Glaxo Group Ltd Compounds
PL1737850T3 (en) 2004-04-19 2008-02-29 Symed Labs Ltd A novel process for the preparation of linezolid and related compounds
DE102004030099A1 (en) 2004-06-22 2006-01-12 Grünenthal GmbH Saturated and unsaturated 3-pyridylbenzocycloalkylmethylamines as serotonin and / or norepinephrine reuptake inhibitors and / or μ-opioid receptor modulators
EP1768967B1 (en) 2004-07-20 2009-04-22 Symed Labs Limited Novel intermediates for linezolid and related compounds
EP1793359A4 (en) 2004-08-31 2010-05-19 Panasonic Corp Content purchase processing terminal ,method thereof, and program
US20060074105A1 (en) 2004-09-20 2006-04-06 Serenex, Inc. Substituted quinoline and quinazoline inhibitors of quinone reductase 2
EP1804823A4 (en) 2004-09-29 2010-06-09 Amr Technology Inc Novel cyclosporin analogues and their pharmaceutical uses
ES2338139T3 (en) 2004-12-15 2010-05-04 F. Hoffmann-La Roche Ag FENIL-METANONAS BI- AND TRICYCLES REPLACED AS INHIBITORS OF THE GLICINE I CARRIER (GLYT-1) FOR THE TREATMENT OF ALZHEIMER'S DISEASE.
ES2334578T3 (en) 2005-02-07 2010-03-12 F. Hoffmann-La Roche Ag PHENYL-METHANONE REPLACED BY HETEROCICLE AS INHIBITORS OF THE GLICINE TRANSPORTER 1.
AU2006228957A1 (en) 2005-04-01 2006-10-05 Methylgene Inc. Inhibitors of histone deacetylase
EP1877055A4 (en) 2005-05-06 2008-10-01 Apath Llc 4-aminoquinoline compounds for treating virus-related conditions
TW200716636A (en) 2005-05-31 2007-05-01 Speedel Experimenta Ag Heterocyclic spiro-compounds
JP5258561B2 (en) 2005-07-15 2013-08-07 アルバニー モレキュラー リサーチ， インコーポレイテッド Aryl and heteroaryl substituted tetrahydrobenzazepines and their use to block reuptake of norepinephrine, dopamine and serotonin
US7514068B2 (en) 2005-09-14 2009-04-07 Concert Pharmaceuticals Inc. Biphenyl-pyrazolecarboxamide compounds
BRPI0619633A2 (en) 2005-12-01 2011-10-04 Elan Pharm Inc 5- (arylsulfonyl) -pyrazolopiperidines
EP2032566A4 (en) 2006-06-12 2009-07-08 Merck Frosst Canada Ltd Azetidine derivatives as inhibitors of stearoyl-coenzyme a delta-9 desaturase
GB0619176D0 (en) 2006-09-29 2006-11-08 Lectus Therapeutics Ltd Ion channel modulators & uses thereof
US8796267B2 (en) 2006-10-23 2014-08-05 Concert Pharmaceuticals, Inc. Oxazolidinone derivatives and methods of use
RU2460725C2 (en) 2007-02-15 2012-09-10 Ф. Хоффманн-Ля Рош Аг Novel 2-aminooxazolines as taar1 ligands
KR20100105802A (en) 2007-04-19 2010-09-29 콘서트 파마슈티컬즈, 인크. Deuterated morpholinyl compounds
US7531685B2 (en) 2007-06-01 2009-05-12 Protia, Llc Deuterium-enriched oxybutynin
CN101679295A (en) 2007-06-06 2010-03-24 帝斯曼知识产权资产管理有限公司 Novel 5-substituted hydantoins
CN101784533B (en) * 2007-08-22 2013-08-21 艾博特股份有限两合公司 4-benzylaminoquinolines, pharmaceutical compositions containing them, and their use in therapy
WO2009035598A1 (en) 2007-09-10 2009-03-19 Concert Pharmaceuticals, Inc. Deuterated pirfenidone
US20090118238A1 (en) 2007-09-17 2009-05-07 Protia, Llc Deuterium-enriched alendronate
US20090082471A1 (en) 2007-09-26 2009-03-26 Protia, Llc Deuterium-enriched fingolimod
US20090088416A1 (en) 2007-09-26 2009-04-02 Protia, Llc Deuterium-enriched lapaquistat
EP2209774A1 (en) 2007-10-02 2010-07-28 Concert Pharmaceuticals Inc. Pyrimidinedione derivatives
US20090105338A1 (en) 2007-10-18 2009-04-23 Protia, Llc Deuterium-enriched gabexate mesylate
US8410124B2 (en) 2007-10-18 2013-04-02 Concert Pharmaceuticals Inc. Deuterated etravirine
AU2008317375B2 (en) 2007-10-26 2013-02-28 Concert Pharmaceuticals, Inc. Deuterated darunavir
US8653100B2 (en) 2008-04-01 2014-02-18 Abbvie Inc. Tetrahydroisoquinolines, pharmaceutical compositions containing them, and their use in therapy
WO2010020548A1 (en) 2008-08-20 2010-02-25 F. Hoffmann-La Roche Ag Glyt1 receptor antagonists
AU2009289846B2 (en) 2008-09-02 2014-10-16 Sanofi-Aventis Substituted aminoindanes and analogs thereof, and the pharmaceutical use thereof
DE102008047162A1 (en) 2008-09-15 2010-03-25 Institut Für Solarenergieforschung Gmbh Rear contact solar cell with integrated bypass diode and manufacturing method thereof
AR075442A1 (en) 2009-02-16 2011-03-30 Abbott Gmbh & Co Kg AMINOTETRALINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM AND THEIR USES IN THERAPY
TW201038569A (en) 2009-02-16 2010-11-01 Abbott Gmbh & Co Kg Heterocyclic compounds, pharmaceutical compositions containing them, and their use in therapy
EP2246331A1 (en) 2009-04-24 2010-11-03 Westfälische Wilhelms-Universität Münster NR2B-selective NMDA-receptor antagonists
WO2010138901A1 (en) 2009-05-29 2010-12-02 Biogen Idec Ma Inc Carboxylic acid-containing compounds, derivatives thereof, and related methods of use
US8846743B2 (en) 2010-08-13 2014-09-30 Abbott Laboratories Aminoindane derivatives, pharmaceutical compositions containing them, and their use in therapy
US9045459B2 (en) 2010-08-13 2015-06-02 AbbVie Deutschland GmbH & Co. KG Phenalkylamine derivatives, pharmaceutical compositions containing them, and their use in therapy
US8877794B2 (en) 2010-08-13 2014-11-04 Abbott Laboratories Phenalkylamine derivatives, pharmaceutical compositions containing them, and their use in therapy
US8883839B2 (en) 2010-08-13 2014-11-11 Abbott Laboratories Tetraline and indane derivatives, pharmaceutical compositions containing them, and their use in therapy
US9309200B2 (en) 2011-05-12 2016-04-12 AbbVie Deutschland GmbH & Co. KG Benzazepine derivatives, pharmaceutical compositions containing them, and their use in therapy
WO2013020930A1 (en) 2011-08-05 2013-02-14 Abbott Gmbh & Co. Kg Aminochromane, aminothiochromane and amino-1,2,3,4-tetrahydroquinoline derivatives, pharmaceutical compositions containing them, and their use in therapy
JP2014533675A (en) 2011-11-18 2014-12-15 アッヴィ・ドイチュラント・ゲー・エム・ベー・ハー・ウント・コー・カー・ゲー N-substituted aminobenzocycloheptene, aminotetralin, aminoindane and phenalkylamine derivatives, pharmaceutical compositions containing them, and their use in therapy
US9365512B2 (en) 2012-02-13 2016-06-14 AbbVie Deutschland GmbH & Co. KG Isoindoline derivatives, pharmaceutical compositions containing them, and their use in therapy

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993013073A1 (en) * 1991-12-23 1993-07-08 The Boots Company Plc Substituted tetrahydroisoquinolines and their use as therapeutic agents

Also Published As

Publication number Publication date
US20130203749A1 (en) 2013-08-08
EP2271625B1 (en) 2012-09-12
EP2527328A1 (en) 2012-11-28
US8653100B2 (en) 2014-02-18
ES2397764T3 (en) 2013-03-11
US8957089B2 (en) 2015-02-17
WO2009121872A2 (en) 2009-10-08
JP2011517453A (en) 2011-06-09
CN103224487A (en) 2013-07-31
CN102083797A (en) 2011-06-01
US20110105502A1 (en) 2011-05-05
JP5554319B2 (en) 2014-07-23
CA2720004A1 (en) 2009-10-08
EP2271625A2 (en) 2011-01-12
MX2010010773A (en) 2011-04-11
CN102083797B (en) 2014-06-04

Similar Documents

Publication Publication Date Title
WO2009121872A3 (en) Tetrahydroisoquinolines, pharmaceutical compositions containing them, and their use in therapy
MX2011008634A (en) Aminotetraline derivatives, pharmaceutical compositions containing them, and their use in therapy.
MX2009014235A (en) 4-benzylaminoquinolines, pharmaceutical compositions containing them, and their use in therapy.
WO2012020131A3 (en) Aminoindane derivatives, pharmaceutical compositions containing them, and their use in therapy
MX2014009757A (en) Isoindoline derivatives, pharmaceutical compositions containing them, and their use in therapy.
MX2014006004A (en) N-substituted aminobenzocycloheptene, aminotetraline, aminoindane and phenalkylamine derivatives, pharmaceutical compositions containing them, and their use in therapy.
MY147994A (en) Azabiphenylaminobenzoic acid derivatives as dhodh inhibitors
WO2008148074A3 (en) Inhibitors of mtor and methods of treatment using same
WO2012046030A3 (en) Phosphodiesterase inhibitors
MX2016004936A (en) Aminochromane, aminothiochromane and amino-1,2,3,4-tetrahydroquin oline derivatives, pharmaceutical compositions containing them, and their use in therapy.
TN2011000414A1 (en) Pharmaceutical composition comprising linagliptin and optionally a sglt2 inhibitors, and uses thereof
MX2010006799A (en) Benzofuropyrimidinones as protein kinase inhibitors.
WO2012088266A3 (en) Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3
EA201100030A1 (en) PYRAZOL COMPOUNDS 436
MY149731A (en) Compounds
IL193762A (en) Compounds useful in inhibiting dgat1-related disorders, pharmaceutical compositions comprising them and use thereof in preparation of medicaments
IL211825A (en) Pyridine and pyrimidine based compounds for use as wnt signaling pathway inhibitors, pharmaceutical formulations comprising such compounds and use thereof as medicaments for the treatment and/or prophylaxis of cancer
UA93709C2 (en) 12-imidazolyl-1-dodecanol and use thereof in the preparation of pharmaceutical compositions
MX2015011614A (en) Pyrrolidine derivatives, pharmaceutical compositions containing them, and their use in therapy.
MX2009013501A (en) Piperidine compounds and uses thereof.
MX2009004017A (en) The uses of the carboxy-amido-triazole compounds and salts thereof.
WO2012135619A3 (en) Intranasal benzodiazepine pharmaceutical compositions
MX2016004934A (en) Aminotetraline and aminoindane derivatives, pharmaceutical compositions containing them, and their use in therapy.
WO2009062576A8 (en) Benzimidazoledihydrothiadiazinone derivatives as fructose-1,6-bisphosphatase inhibitors, and pharmaceutical compositions comprising same
MX2013006004A (en) 5-methyl-1-(naphthalen-2-yl)-1h-pyrazole derivatives and their use in potentiating the effect of opioid analgesics.

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200980121237.2

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09727055

Country of ref document: EP

Kind code of ref document: A2

DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2720004

Country of ref document: CA

Ref document number: 2009727055

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2011502370

Country of ref document: JP

Ref document number: MX/A/2010/010773

Country of ref document: MX

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 12933326

Country of ref document: US